Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction

Transplantation

Volumn 78, Issue 6, 2004, Pages 919-924

  Cai, Junchao ^a   Terasaki, Paul I ^a   Bloom, Debra D ^b   Torrealba, Jose R ^b   Friedl, Andreas ^b   Sollinger, Hans W ^b   Knechtle, Stuart J ^b,c  

^a TERASAKI FOUNDATION LABORATORY   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALLOANTIBODY; CREATININE; HLA ANTIBODY; HLA ANTIGEN; METHYLPREDNISOLONE; RAPAMYCIN;

ADULT; ANTIBODY PRODUCTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DRUG INFUSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HLA SYSTEM; HUMAN; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MONOTHERAPY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY FORMATION; ANTIGENS, CD4; ANTIRHEUMATIC AGENTS; CREATININE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HLA-D ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; SIROLIMUS;

EID: 4644290312     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000134398.86243.81     Document Type: Article

References (28)

1. Strober S, Dhillon M, Schubert M, et al. Acquired immune tolerance to cadaveric renal allografts, A study of three patients treated with total lymphoid irradiation. N Engl J Med 1989; 321: 28.
2. Waldmann H, Cobbold S. Monoclonal antibodies for the induction of transplantation tolerance. Curr Opin Immunol 1993; 5: 753.
3. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative Campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 352: 408.
4. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003; 76: 120.
5. Collins AB, Schneeberger EE, Pascual MA, et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10: 2208.
6. Knechtle SJ, Pirsch JD, Fechner JH Jr., et al. Campath-1H induction plus sirolimus monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 722.
7. Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003; 3: 665.
8. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735.
9. Frost AE, Jammal CT, Cagle PT. Hyperacute rejection following lung transplantation. Chest 1996; 110: 559.
10. Higuchi ML, Bocchi E, Fiorelli A, et al. Histopathologic aspects of hyperacute graft rejection in human cardiac transplantation. A case report. Arq Bras Cardiol 1989; 52: 39.
11. Scornik JC, Zander DS, Baz MA, et al. Susceptibility of lung transplants to preformed donor-specific HLA antibodies as detected by flow cytometry. Transplantation 1999; 68: 1542.
12. Lee PC, Terasaki PI, Takemoto SK, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002; 74: 1192.
13. Worthington JE, Martin S, Al-Husseini DM, et al. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003; 75: 1034.
14. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004; 4: 438.
15. Cai J, Gjertson DW, Terasaki PI. Maintenance immunosuppressive treatment and graft half-life. In: Cecka JM, Terasaki PI, eds. Clinical Transplants 2002, Los Angeles, CA: UCLA Immunogenetics Center, 2003: p. 359.
16. Theruvath TP, Saidman SL, Mauiyyedi S, et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation 2001; 72: 77.
17. Piazza A, Poggi E, Borrelli L, et al. Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: posttransplant analysis using flow cytometric techniques. Transplantation 2001; 71: 1106.
18. Supon P, Constantino D, Hao P, et al. Prevalence of donor-specific anti-HLA antibodies during episodes of renal allograft rejection. Transplantation 2001; 71: 577.
19. Rebello P, Cwynarski K, Varughese M, et al. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 2001; 3: 261.
20. Blazar BR, Taylor PA, Sehgal SN, et al. Sirolimus, a potent inhibitor of T-cell function, prevents graft rejection in murine recipients of allogeneic T-cell-depleted donor marrow. Blood 1994; 83: 600.
21. Vanrenterghem Y. The use of mycophenolate mofetil (CellCept) in renal transplantation. Nephron 1997; 76: 392.
22. Feucht HE. Complement C4d in graft capillaries-the missing link in the recognition of humoral alloreactivity. Am J Transplant 2003; 3: 646.
23. Bohmig GA, Exner M, Habicht A, et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13: 1091.
24. Lederer SR, Kluth-Pepper B, Schneeberger H, et al. Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int 2001; 59: 334.
25. Pei R, Lee JH, Shih NJ, et al. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003; 75: 43.
26. Zwirner NW, Fernandez-Vina MA, Stastny P. MICA, a new polymorphic HLA-related antigen, is expressed mainly by keratinocytes, endothelial cells, and monocytes. Immunogenetics 1998; 47: 139.
27. Faulk WP, Rose M, Meroni PL, et al. Antibodies to endothelial cells identify myocardial damage and predict development of coronary artery disease in patients with transplanted hearts. Hum Immunol 1999; 60: 826.
28. Sumitran-Karuppan S, Tyden G, Reinholt F, et al. Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells. Transpl Immunol 1997; 5: 321.